journal article·2016-10-02Open access

Optimization, in vitro cytotoxicity and penetration capability of deformable nanovesicles of paclitaxel for dermal chemotherapy in Kaposi sarcoma

Kamla Pathak, Vijay Sharma, Meenu Sharma

Abstract

Although much research has been published on ways to overcome the low oral bioavailability of paclitaxel, exploration of novel drug delivery systems that can target paclitaxel deep in to the dermal areas in AIDS-related Kaposi sarcoma (KS) have not yet been reported. Our aim was to develop deformable nanovesicles of paclitaxel capable of being used in dermal chemotherapy, especially deep into the dermal areas of AIDS related KS. Deformable nanovesicular formulations (TS1-TS15) composed of soya lecithin and span80 were prepared by the rotary evaporation sonication method within the constraints of our Box-Behnken design. The formulations were subjected to vesicle characterization and ex vivo permeation. The optimized vesicular suspension was formulated as a gel and assessed for in vitro cytotoxicity and penetration characteristics by confocal laser scanning microscopy (CLSM). TS9 with vesicle size characteristics of 185.76 ± 2.15 nm, zeta potential of -23.2 mV, deformability index = 138.02 and cumulative drug permeation of 89.80 ± 1.84% was identified as the optimized formulation. TEM revealed spherical vesicles with firm boundaries that were stable at 4 °C. TS9 was developed as carbopol 934P gel (TG) and compared with the control gel (CG) made with the pure drug (paclitaxel). TG showed significantly higher (p < 0.05) in vitro drug permeation and flux compared to the CG. In vitro cytotoxicity study on KSY-1 cell lines revealed higher IC50 (≤17) for TS against IC50 ≤19 for TG. CLSM confirmed the penetrating potential of transfersomes via TG to the dermal layers of skin, the proposed target site. Conclusively, deformable nonovesicles of paclitaxel appear as a feasible alternative to the conventional formulations of paclitaxel in the management of AIDS-related KS.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Immunotherapy and Immune Responses · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Rajiv Academy for Pharmacy, N.H. #2, Delhi–Mathura Road, P.O. Chhatikara, Mathura, Uttar Pradesh, India

References (31)

Show source-provided references
1. 10.1016/j.ijpharm.2013.10.04510.1016/j.ijpharm.2013.10.045 ↗
2. 10.1080/00401706.1960.1048991210.1080/00401706.1960.10489912 ↗
3. 10.1007/s10544-011-9590-y10.1007/s10544-011-9590-y ↗
4. 10.1016/0168-3659(95)00056-E10.1016/0168-3659(95)00056-E ↗
5. 10.1016/j.ijpharm.2008.04.00510.1016/j.ijpharm.2008.04.005 ↗
6. 10.3389/fmicb.2012.0014110.3389/fmicb.2012.00141 ↗
7. Douglas JL · Transl Biomed · 2010 · 1 · 172
8. Duangjit S · J Drug Deliv · 2011 · 418316
9. 10.1016/j.ijpharm.2010.06.03410.1016/j.ijpharm.2010.06.034 ↗
10. 10.1016/j.aca.2007.07.01110.1016/j.aca.2007.07.011 ↗
11. Ghanbarzadeh S · BioMed Res Int · 2013
12. 10.1103/PhysRevB.52.419810.1103/PhysRevB.52.4198 ↗
13. 10.1016/j.ijpharm.2005.07.02610.1016/j.ijpharm.2005.07.026 ↗
14. 10.1093/annonc/mdj10010.1093/annonc/mdj100 ↗
15. 10.1016/j.jconrel.2006.04.01610.1016/j.jconrel.2006.04.016 ↗
16. 10.1016/j.jhazmat.2009.07.02510.1016/j.jhazmat.2009.07.025 ↗
17. 10.1016/j.drudis.2012.06.01310.1016/j.drudis.2012.06.013 ↗
18. 10.2174/13895571280049392410.2174/138955712800493924 ↗
19. 10.2174/156720181166614060915494910.2174/1567201811666140609154949 ↗
20. 10.1007/s10637-010-9421-710.1007/s10637-010-9421-7 ↗
21. 10.1073/pnas.76.6.275010.1073/pnas.76.6.2750 ↗
22. 10.1016/j.hivar.2011.04.00210.1016/j.hivar.2011.04.002 ↗
23. 10.1046/j.1365-2133.1998.02166.x10.1046/j.1365-2133.1998.02166.x ↗
24. 10.1016/S0378-5173(01)00986-310.1016/S0378-5173(01)00986-3 ↗
25. 10.1615/CritRevTherDrugCarrierSyst.v22.i1.2010.1615/CritRevTherDrugCarrierSyst.v22.i1.20 ↗
26. 10.1016/j.jconrel.2004.11.02010.1016/j.jconrel.2004.11.020 ↗
27. Toropainen E · Invest Ophthalmol Visual Sci · 2001 · 42 · 2942
28. Van Asperen J · A. Clin Cancer Res · 1998 · 4 · 2293
29. 10.1016/j.nano.2011.07.00410.1016/j.nano.2011.07.004 ↗
30. Wissing SA · J Cosmet Sci · 2001 · 52 · 313
31. 10.4103/2230-973X.13834210.4103/2230-973X.138342 ↗